Home › Compugen Extends Discovery Capabilities To Additional Immunomodulatory Proteins
 

Keywords :   


Compugen Extends Discovery Capabilities To Additional Immunomodulatory Proteins

2014-07-30 10:01:01| drugdiscoveryonline Home Page

Compugen Ltd. recently announced the extension of its predictive discovery capability to identify immunomodulatory proteins in addition to the B7/CD28-like proteins that have been the focus of the Company’s Pipeline Program to date. The initial utilization of this extended capability resulted in the discovery of four novel immunomodulatory proteins predicted to act as immune checkpoints

Tags: additional discovery capabilities proteins

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
10.05Faisal Islam: Economy is getting better but people may not notice
10.05Sulfate-Free Foamable Solid Cleanser Patented by Johnson & Johnson
10.05Farm Progress America, May 10, 2024
10.05Farm Progress America, May 10, 2024
10.05Comcast releases research on how viewers discover new TV content
10.05Samba TV uses GenAI to provide actionable context for video ads
10.05Roku unveils screensaver ad integrations, ad partnerships and fresh content
10.05Samsung TV Plus partners with MLB, PGA Tour, F1 and ONE Championship
More »